Slide 1: Making improvements in life possible
Making improvements in life possible Investor Introduction Fourth quarter 2022
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Q4 2022 Investor Resource Book 3
Slide 4: QIAGEN provides solutions to uncover molecular insights
QIAGEN provides solutions to uncover molecular insights – faster, better and more efficiently – from Sample to Insight Biological Sample to Valuable sample Insight solutions molecular insights • Sample Technologies • Advancing knowledge about the building • Assay Technologies blocks of life – DNA, R
Slide 5: QIAGEN at a glance
QIAGEN at a glance Our products support scientists and clinicians to advance scientific discovery and improve patient outcomes A global company with scale Balanced customer markets $2.2 bn ~50% ~50% >500,000 (2021 sales) Molecular customers Life Diagnostics Sciences worldwide Diverse global presence
Slide 6: There is an unprecedented need for molecular research and testing
There is an unprecedented need for molecular research and testing to tackle the health challenges of our time Our knowledge about Tuberculosis is still Cancer remains a Infectious diseases the building blocks of one of the world’s leading cause of have been – and life – DNA, RNA and most significant
Slide 7: Our products are found in laboratories worldwide
Our products are found in laboratories worldwide - from young scientists to Nobel laureates Q4 2022 Investor Resource Book 7
Slide 8: We are COVID relevant – but not COVID dependent
We are COVID relevant – but not COVID dependent >750 million COVID-19 tests in 2021 relied on QIAGEN products Testing Surveillance • RNA sample preparation • Immune level testing • PCR testing solutions • NGS variant monitoring • OEM components • Wastewater testing for other suppliers Q4 2022 Invest
Slide 9: Ready to serve public health needs across the globe
And we are ready to serve public health needs across the globe Determined to leave no country behind with a portfolio of dedicated tests and strategic partnerships TB testing for low-resource Testing for high-risk human Sample technologies high-burden regions with papillomavirus (HPV) using supporti
Slide 10: Global presence with a focus on attractive developed and emerging markets
Global presence with a focus on the most attractive developed and emerging markets Our global and regional headquarters Venlo Netherlands 35 subsidiaries Global HQ Germantown Maryland Americas HQ Distribution Hilden partners in over Germany in over 25 EMEA HQ Shanghai China Asia-Pacific HQ 60 countr
Slide 11: Our Strategy: Focus on areas to build and maintain leading positions
Our Strategy: Focus on areas to build and maintain leading positions Expanding on solid leadership Early commercialization phases with strong growth potential Nr. 1 in QuantiFERON for QIAstat-Dx for NeuMoDx for Leading the way Sample technologies immune response near-patient syndromic mid- to high-t
Slide 12: Five pillars of growth: Advancing key drivers to capture large opportunities
Five pillars of growth: Advancing key drivers to capture large opportunities Targeting >$6 billion of our >$11 billion total addressable market Sample technologies QuantiFERON QIAstat-Dx NeuMoDx QIAcuity • Leading reputation, • Fully automated • Sample prep in <1 • Faster time to result • Rapid time
Slide 13: Five pillars of growth: Expected trends in 2022 and beyond
Five pillars of growth: Expected trends in 2022 and beyond Cumulative 2022 placements sales goals Post-COVID dynamics (As of Jan 2022) (CER) QIAsymphony >3,000 Sustainable low- to mid- Sample technologies QIAcube >13,000 >$750 m single-digit CER growth EZ1 and EZ2 >4,800 Sustainable low-double-digit
Slide 14: FY 2021: Solid growth trends beyond COVID in all product groups
FY 2021: Solid growth trends beyond COVID in all product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) +19% CER +19% CER $2,252 $2,252 $1,870 $1,870 851 Sample technologies +4% CER 1,547 Non-COVID 804 product groups 1,252 Diagnostic +
Slide 15: FY 2021: Investing in the business while building value
FY 2021: Investing in the business while building value Adj. operating income Adjusted EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) Targeted investments into key drivers $639 ~65% of R&D spending focused on five pillars of growth 190 $458 $755 $2.65 Disciplined operating
Slide 16: Outlook: Q4 and FY 2022
Outlook: Q4 and FY 2022 Q4 2022 outlook Updated FY 2022 outlook ~ $2.25 billion CER Net sales > $520 million CER Adverse FX impact of ~ -6 p.p. Anticipated currency impact Adverse FX impact of ~ -7 p.p (Previously: ≥ $2.2 bn CER) Non-COVID product groups Double-digit CER growth Double-digit CER grow
Slide 17: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of December 31, 2021 Maturities of debt instruments $2.02 billion $1.06 billion (In $ millions) Cash and short-term U.S. Private Placement Schuldschein Convertible Bonds Convertible investments Bonds 117 2023 2024 635 2027 $957
Slide 18: Supporting growth while increasing returns to shareholders
Supporting growth while increasing returns to shareholders Healthy cash flow trends Invest in the business 500 1.8 1.5x Fuel sustainable and profitable 1.6x 0.9x 1.5x 1.6 growth, especially in the five pillars 1.4x 400 1.4 458 449 1.2 Enhance value with M&A 300 359 1.0 Ongoing disciplined approach w
Slide 19: Why invest in QIAGEN: Strong de-risked investment case
Why invest in QIAGEN: Strong de-risked investment case with compelling differentiation Highly recurring Broad geographic Diversified customer revenues reach base Sales driven by steady customer Robust structures securing access to Well-balanced sales split between shipments of high margin consumable
Slide 20: Reporting sales in product groups
Reporting sales in product groups QIAGEN Five pillars of growth Sample QIAcuity product groups technologies(1) digital PCR(3) QIAstat-Dx NeuMoDx QuantiFERON Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control includin
Slide 21: Q3 2022 results
Q3 2022 results Exceeded outlook with 18% CER sales growth in non-COVID portfolio
Slide 22: Q3 2022: Double-digit CER growth in non-COVID portfolio
Q3 2022: Double-digit CER growth in non-COVID portfolio Net sales (CER)(1) Q3 2022: $533 million vs. ≥ $510 million outlook + 18% non-COVID products - 43% COVID-19 products Adjusted EPS (CER)(2) Q3 2022: $0.55 CER vs. ≥ $0.48 CER outlook 1) Net sales: $500 million, -7% at actual rates, 0% at CER vs.
Slide 23: Q3 2022: Solid performance with clear strategy execution
Q3 2022: Solid performance with clear strategy execution Ongoing strong trends Executing on key Strong operating Increasing 2022 in non-COVID business 2022 objectives cash flow full-year outlook +18% CER growth in 13 new biopharma assays +34% rise to $591 million in Sales: ~ $2.25 billion CER non-CO
Slide 24: Q3 2022: +18% CER growth in non-COVID product groups
Q3 2022: +18% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -7% -7% (0% CER) (0% CER) $535 $535 $500 $500 Sample - 2% CER Non-COVID 202 technologies product groups 183 376 + 18% CER 417 Diagnostic + 4%
Slide 25: Q3 2022: Solid demand for non-COVID products
Q3 2022: Solid demand for non-COVID products Americas • US: +7% CER non-COVID growth absorbed lower COVID sales • Brazil: Double-digit CER gains • Canada: Single-digit CER growth Europe / Middle East / Africa Americas EMEA Asia-Pacific / • Germany, Austria and Netherlands: Japan Strong double-digit
Slide 26: Q3 2022: Maintaining strong cash flow and healthy balance sheet
Q3 2022: Maintaining strong cash flow and healthy balance sheet Operating cash flow Free cash flow Leverage (In $ millions) (In $ millions) (Net debt / adj. EBITDA) Targeted investments into Five Pillars + 40% + 34% High level of R&D investments into menu expansion for QIAstat-Dx, NeuMoDx and 591 $5
Slide 27: QIAstat-Dx: Viral vesicular panel to address monkeypox detection
QIAstat-Dx: Viral vesicular panel to address monkeypox detection RUO panel for research and epidemiological surveillance Pathogens differentiated by the QIAstat-Dx Viral Vesicular Panel Monkeypox virus (MPXV) clade 1 MPXV clade 2 Herpes simplex virus 1 Human herpes virus 6 Herpes simplex virus 2 Ent
Slide 28: NeuMoDx: Expanding CE-IVD menu to 16 tests
NeuMoDx: Expanding CE-IVD menu to 16 tests CE-IVD Hepatitis B Blood-borne viruses Hepatitis C Human Immunodeficiency Virus Cytomegalovirus Epstein Barr Virus 2.0 BK Virus Transplant Herpes Simplex Virus 1/2 Adenovirus Human Herpes Virus 6 Chlamydia / Gonorrhea Guillain–Barré syndrome Woman’s health
Slide 29: QIAcuity: Capturing attractive biopharma growth opportunities
QIAcuity: Capturing attractive biopharma growth opportunities 13 new kits and and custom assays to serve Biopharma customers Biopharma customer preference: QIAcuity Eight • 10 QIAcuity Cell and Gene Therapy (CGT) dPCR Assays • 3 QIAcuity Residual DNA Quantification Kits • Custom assay design provide
Slide 30: Leveraging a comprehensive Liquid Biopsy portfolio
Leveraging a comprehensive Liquid Biopsy portfolio Addressing opportunities in research and clinical applications to unlock insights from blood Liquid Non-Invasive Cancer Growing Transplant Biopsy Prenatal research and monitoring market trends applications Testing (NIPT) oncology • Expansion of cfDN
Slide 31: Committed to building a sustainable business
Committed to building a sustainable business QIAGEN 2021 Sustainability Report Published in August 2022 https://www.qiagen.com/sustainability Environment Social Governance Visible progress in lowering Committed to leaving Ensuring responsible business greenhouse gas intensity no one behind conduct f
Slide 32: Key messages
Key messages Q3 2022: Solid results exceeded outlook, driven by 18% CER sales growth 01 in non-COVID portfolio FY 2022 outlook: Increased sales and adj. EPS due to Q3 performance, 02 reaffirming double-digit CER non-COVID sales growth 03 Making progress on advancing strategy focused on 5 Pillars of
Slide 33: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Q4 / FY 2022 results February 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q1 2023 results May 2023 E-mail: phoebe.loh@qiagen.com Annual General Meeting June 2023 Alexandra Koenig Share information Coordinator Inv